Literature DB >> 16085540

Gene expression profiling in the myelodysplastic syndromes.

Andrea Pellagatti1, Carrie Fidler, James S Wainscoat, Jacqueline Boultwood.   

Abstract

The myelodysplastic syndromes (MDS) are a heterogeneous group of haematopoietic malignancies, characterized by blood cytopenias, ineffective hematopoiesis and hypercellular bone marrow. Several genetic alterations have been reported in MDS but these are not MDS-specific and the underlying molecular causes of the disease remain poorly understood. Gene expression microarray technology allows the simultaneous parallel analysis of many thousands of genes and has already provided novel insights into cancer pathogenesis. In this review we discuss the results of several recent studies which utilize the enormous power of microarray technology for the study of MDS. Several exciting findings have emerged from these early studies that highlight the potential of this technology to further our understanding of the molecular pathogenesis of this disorder. It is clear, however, that these findings should be confirmed in larger sets of MDS patients.

Entities:  

Mesh:

Year:  2005        PMID: 16085540     DOI: 10.1080/10245330500065680

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  4 in total

1.  Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.

Authors:  Merav Bar; Derek Stirewalt; Era Pogosova-Agadjanyan; Vitas Wagner; Ted Gooley; Nissa Abbasi; Ravi Bhatia; H Joachim Deeg; Jerald Radich
Journal:  Transl Oncogenomics       Date:  2008-05-29

2.  Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.

Authors:  Wolf C Prall; Akos Czibere; Franck Grall; Dimitrios Spentzos; Ulrich Steidl; Aristoteles Achilles Nikolaus Giagounidis; Andrea Kuendgen; Hasan Otu; Astrid Rong; Towia A Libermann; Ulrich Germing; Norbert Gattermann; Rainer Haas; Manuel Aivado
Journal:  Int J Hematol       Date:  2009-01-20       Impact factor: 2.490

3.  Evolving new treatment for myelodysplastic syndromes.

Authors:  Yataro Yoshida
Journal:  Int J Hematol       Date:  2007-11       Impact factor: 2.490

4.  Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms.

Authors:  Gabriela Silva; Bruno A Cardoso; Hélio Belo; António Medina Almeida
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.